Senti Biosciences raises up to $47.6M in Series A preferred stock and warrants private placement

Senti Biosciences, Inc.

Issued up to 21,157 shares of Series A Convertible Preferred at $2,250/share, with warrants for up to 31.7M common shares at $2.30.
Initial closing of $37.6M (16,713 preferred shares) expected Dec 5, 2024; option for additional $9.9M by Dec 27, 2024.
Series A Preferred carries 18% annual cumulative dividend, convertible into common at $2.25 after stockholder approval.
Director Omid Farokhzad resigned; Frances Schulz (former EY partner) and Donald Tang (Celadon designee) appointed to board.
Net proceeds to fund working capital, R&D, and SENTI-202 program advancement.

item 1.01 item 5.03 item 2.03 item 3.02 item 3.03 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Frances D. Schulz

Director

SNTI · Senti Biosciences, Inc.

Filed: December 2, 2024, 6:59 PM ET

On December 2, 2024, upon the recommendation of its Nominating and Corporate Governance Committee, the Board unanimously appointed Frances D. Schulz to fill a newly created vacancy on the Board resulting from the resignation of Dr. Farokhzad, such appointment to be effective upon the initial closing of the Offering.

Departed

Omid Farokhzad

Director

SNTI · Senti Biosciences, Inc.

Effective: 2024-11-25
Successor: Frances D. Schulz
Filed: December 2, 2024, 6:59 PM ET

On November 25, 2024, Omid Farokhzad, M.D., a member of the Board and the Audit Committee of the Board, notified the Board of his resignation as a director of the Company and all committees thereof, effective November 25, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Frances D. Schulz was appointed as Director at Senti Biosciences, Inc..

Action: appointed
Role: Director

Exact text from the filing

On December 2, 2024, upon the recommendation of its Nominating and Corporate Governance Committee, the Board unanimously appointed Frances D. Schulz to fill a newly created vacancy on the Board resulting from the resignation of Dr. Farokhzad, such appointment to be effective upon the initial closing of the Offering.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Omid Farokhzad resigned as Director at Senti Biosciences, Inc..

Action: resigned
Role: Director

Exact text from the filing

On November 25, 2024, Omid Farokhzad, M.D., a member of the Board and the Audit Committee of the Board, notified the Board of his resignation as a director of the Company and all committees thereof, effective November 25, 2024.

View on SEC.gov

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-048184

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.